HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors. The funds will be used to accelerate the commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection technologies, expand artificial intelligence capabilities, and for general corporate purposes.
HeartBeam is a medical technology company focused on transforming the detection and monitoring of critical cardiac conditions. The company is developing the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
The offering represents a significant milestone for HeartBeam as it seeks to commercialize its innovative cardiac monitoring solutions. With over 20 issued patents related to its technology, HeartBeam is positioning itself to redefine cardiac health management. The additional capital will support the company's efforts to bring its FDA-cleared products to market and expand its AI-driven capabilities. For more details on the offering, refer to the full press release at https://ibn.fm/9iNYY. For the latest news and updates on HeartBeam, visit the company’s newsroom at https://ibn.fm/BEAT. Information on the cleared indications for use of HeartBeam’s technology can be found at https://www.heartbeam.com/indications.
The successful closing of this offering underscores investor confidence in HeartBeam’s technology and its potential to impact cardiac care. By enabling ECG monitoring outside clinical settings, HeartBeam aims to facilitate early detection and management of heart conditions, potentially reducing the burden on healthcare systems and improving patient outcomes. The proceeds will be instrumental in scaling up manufacturing, expanding sales and marketing efforts, and advancing research and development initiatives.
